Agios Pharmaceuticals (AGIO) Receivables (2014 - 2022)

Agios Pharmaceuticals has reported Receivables for 9 years, with the latest figure at $2.2 million in Q4 2022.

• For the quarter ending Q4 2022, Receivables fell 49.61% year-over-year to $2.2 million; the trailing twelve-month figure through Dec 2022 stood at $2.2 million (down 49.61% YoY), and the FY2022 full-year result was $2.2 million, down 49.61% from the prior year.
• Receivables for Q4 2022 stood at $2.2 million, down from $4.4 million in the prior quarter.
• The five-year high for Receivables was $21.3 million in Q3 2020, with the low at $2.2 million in Q4 2022.
• Historically, Receivables has averaged $10.2 million across 5 years, with a median of $8.9 million in 2019.
• The largest YoY upside for Receivables was 271.8% in 2018 against a maximum downside of 66.51% in 2018.
• Agios Pharmaceuticals' Receivables stood at $7.5 million in 2018, then jumped by 39.17% to $10.5 million in 2019, then jumped by 103.25% to $21.3 million in 2020, then slumped by 79.47% to $4.4 million in 2021, then plunged by 49.61% to $2.2 million in 2022.
• The last three Receivables figures came in at $2.2 million (Q4 2022), $4.4 million (Q4 2021), and $21.3 million (Q3 2020), per Business Quant data.